[Knowledge about Biosimilars in Primary Care: a study by the Spanish Society of Primary Care Physicians (SEMERGEN)].
Por:
Micó-Pérez RM, Payares-Herrera C, Palomo-Jiménez PI, Sánchez-Fierro J, Avendaño-Solá C and Llisterri-Caro JL
Publicada:
1 sep 2018
Resumen:
INTRODUCTION: The objective of this study was to evaluate the awareness
and training needs on biosimilar drugs in Primary Care (PC) physicians.
MATERIAL AND METHODS: Descriptive cross-sectional study based on an
on-line questionnaire with a total of 34 multiple choice questions,
published on the SEMERGEN website. The main Knowledge areas were:
biosimilar definition; regulatory and legal framework; prescription,
traceability, interchangeability and pharmacovigilance; availability of
biosimilars in the PC setting, and the biosimilars contribution to
sustainability. The software used for the analysis and data processing
was the Barbwin 7.5.
RESULTS: An analysis was performed on the responses from 701
questionnaires completed. There was a slight majority (57%) of women
participants. The majority of participant worked in urban centres
(60.91%). The definition of biosimilar was not known by 58% of those
that responded, and 73% were unaware that the management of biosimilars
and generics was not comparable. Most (84%) of those that responded were
not aware that the studies required for the approval of biosimilars is
different from reference biological medicines. Around two-thirds (66%)
those that responded did not know of any biosimilars available in PC
setting, and the 94% were also unaware of the Spanish legal framework
for the management of biosimilar medicines.
CONCLUSIONS: The current knowledge about biosimilars among PC physicians
is low. The critical areas in need of further training include specific
information on biosimilars currently available in PC setting, as well as
key aspects regarding prescription, interchangeability and
pharmacovigilance requirements. Six out of ten doctors do not know of
any biosimilar used in PC in Spain.
Filiaciones:
:
Consultorio Fontanars dels Alforins, EAP Ontinyent, Valencia, España
Payares-Herrera C:
Servicio de Farmacología Clínica, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, España
Palomo-Jiménez PI:
Departamento Médico Sanofi-Aventis, Madrid, España
Sánchez-Fierro J:
Abogado especialista en derecho sanitario, Madrid, España
Avendaño-Solá C:
Servicio de Farmacología Clínica, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, España
:
Centro de Salud Ingeniero Joaquín Benlloch, Valencia, España
|